Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Teamwork takedown: GPs and pharmacists join forces to curb risky pill use in seniors

NCT ID NCT05765656

Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether having a general practitioner and pharmacist work together can help people aged 65 and older safely stop or reduce benzodiazepines (drugs for sleep or anxiety). These medications raise the risk of falls, confusion, and dementia in older adults. The trial will enroll 400 patients and use motivational interviews with pharmacists to support gradual dose reduction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
behavioral intervention (GP-pharmacist collaboration and motivational interviewing)
What this could lead to
If successful, this could provide a practical, team-based approach to safely reduce benzodiazepine use in older adults, potentially lowering risks of falls, confusion, and dementia.
What could go wrong
This is a small, early-stage trial focused on feasibility and acceptance, not on health outcomes. The intervention may not change prescribing habits or patient behavior in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * outpatients aged 65 and over * followed by the general practitioner and the pharmacist of the GP-PO pair * having a prescription for an anxiolytic or hypnotic BZDR prescribed at least 4 times in the past year * the last prescription being less than 3 months old * having been dispensed monthly during the last 3 months * affiliated to a social security scheme * and having given consent to participate in the research. Exclusion Criteria: * patients living in an institution * participating in a clinical trial * with epilepsy * active depression * uncontrolled mental disorders * unable to participate in an interview or answer a questionnaire (demented, non-French speaking, illiterate, deaf, ...) * under guardianship * with a dystonic syndrome * and patients who are not sufficiently autonomous to carry out the steps inherent in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety Benzodiazepine dependence Deprescribing Elderly Health plan implementation Primary care

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Nantes

    RECRUITING

    Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.